A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Fulvestrant (Primary) ; Anastrozole
- Indications Breast cancer
- Focus Therapeutic Use
- 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 23 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.